Skip to main content
Category

In the News

Two UCI researchers named as UCI MIND WAM at Cleveland Clinic Women’s initiative recipients

By Carousel Slider, In the News
Since 2017, UCI MIND has partnered with the Women’s Alzheimer’s Movement (WAM) at Cleveland Clinic, founded by Maria Shriver, to fund the Women’s Initiative. The initiative provides funding for research to better understand why women are at higher risk than men of developing Alzheimer’s disease. This year, the UCI MIND WAM at Cleveland Clinic Women’s Initiative is proud to support two exceptional investigators at UCI with groundbreaking research projects: Dr. María Corrada, Professor of Neurology in the School of Medicine and Professor of Epidemiology and Biostatistics in the Joe C. Wen School of Public Health, will explore "Estrogen Replacement Therapy and…
Read More

On the NYT article “What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials”

By Carousel Slider, Commentary, In the News, Participants
An article in the New York Times is the latest to highlight the safety risks associated with recently approved new treatments for Alzheimer’s disease, lecanemab and donanemab. Being a carrier of the e4 genotype for the apolipoprotein (APOE) gene, is a known risk factor for the most serious side effects of these medications—swelling and bleeding in the brain collectively known as Amyloid Related Imaging Abnormalities (ARIA). The article highlights that in some of the earlier studies of these drugs, participants were not given the opportunity to learn their APOE genotypes. The field has historically been reluctant to disclose APOE results…
Read More

RAMP training program highlighted in local publication

By Carousel Slider, In the News
RAMP trainees stand next to Dr. Lorna Carlin (middle). The Daily Breeze, a local Southern California online news source, highlighted the Research and Mentorship Program (RAMP), a collaborative training initiative between UCI MIND and the UCI School of Medicine to pair 2nd year medical students with faculty studying neurodegenerative diseases. The goal is to inspire future clinicians to pursue research and to specialize in neurology and geriatrics. The program is supported by Dr. Lorna Carlin and Hilarity for Charity, a non-profit organization started by Laura Miller-Rogen and Seth Rogen.  Read the article here
Read More

Dr. Crystal M. Glover will join UCI MIND in 2025 as ORE Core Leader for ADRC

By Carousel Slider, In the News, Participants
We are excited to announce that in January 2025, Dr. Crystal M. Glover will join UCI MIND as the ADRC's Outreach, Recruitment, and Engagement Core Leader.  She will also serve as Associate Professor of Neurology in the UC Irvine School of Medicine. Dr. Glover is a world-renowned applied social psychologist, mixed methodologist, and health disparities researcher focused on social determinants of health as it relates to aging and dementia.  Along with her many international and national leadership roles, Dr. Glover is the inaugural Editor-in-Chief of Alzheimer's and Dementia: Behavior & Socioeconomics of Aging.   She will continue the important work she started…
Read More

MIND Matters | Quarterly Newsletter | Summer 2024

By Carousel Slider, Commentary, Community Events, COVID-19, In the News, Participants
Message from the Director Dear Friends of UCI MIND, This summer, we lost our founder, Dr. Carl Cotman. Under Dr. Cotman’s leadership, UCI became an independent ADRC in 2000. He recruited many of UCI’s most prominent researchers and leaders, such as David Cribbs, Claudia Kawas, and Frank LaFerla. He also lured UCI researchers into collaborative work on dementia, such as Andrea Tenner, Ira Lott, and Marcelo Wood. He launched the Southern California Alzheimer’s Disease Research Conference, now in its 35th year; secured the Neurobiology of Aging NIH training grant, now in its 41st year; and established the UCI ADRC brain…
Read More

Celebrating Hispanic Heritage Month: Honoring Our Commitment to Alzheimer’s Research in Hispanic and Latino Communities

By Carousel Slider, Commentary, In the News
This Hispanic Heritage Month, we proudly recognize the invaluable contributions of our faculty, staff, community partners, and supporters who are dedicated to addressing Alzheimer’s disease and related dementias in the Hispanic and Latino communities. Our mission to advance Alzheimer’s research is strengthened by the passion and collaboration of those working on the front lines to ensure more inclusive research and care. At the forefront of these efforts is our Hispanic Community Advisory Board, led by Dr. Christian Salazar. The Board is instrumental in guiding us on best practices for building strong connections with the more than 1 million Hispanic and…
Read More

AlzForum provides update on MODEL-AD at UCI

By Carousel Slider, Commentary, In the News
AlzForum, the popular online publication for Alzheimer's researchers, published a summary of recent advances from the MODEL-AD teams and highlighted the work of the principal investigators at UCI, Drs. Kim Green, Andrea Tenner, and Frank LaFerla.  The article also called attention to innovative research in the Green Lab, including work by postdoctoral scholar, Dr. Claire Butler and graduate student Kristine Tran.   To read the article, click here.
Read More

Dr. Leigh Turner awarded grant to study ethics of using biocomputing to build neural networks

By Carousel Slider, In the News
Dr. Leigh Turner, Professor of Health, Society and Behavior, School of Public Health As part of a collaborative project with USC and other faculty at UCI, Dr. Leigh Turner has been awarded a 2 million dollar grant from National Science Foundation to use biocomputing and stem cells to build neural networks to one day combat neurodegenerative diseases. Dr. Turner's role will be to study the ethical implications of this potential technology.  Read the article in UCI News.
Read More

Listening to patients unable to communicate

By Carousel Slider, Commentary, In the News
The New York Times recently covered a remarkable study published in the New England Journal of Medicine. The study performed clinical and imaging assessments of 353 adults deemed to be in a minimally conscious or persistent vegetative state. These individuals, who had experienced severe brain injury, stroke, or hypoxia after cardiac arrest were unable to respond to any verbal command. Remarkably, 25% of the patients, when assessed with MRI or EEG, demonstrated an ability to respond to commands with their brain. That is, when they were asked to imagine themselves doing something, their brain response was the same as a normal adult's…
Read More

Keeping sleep in mind: poor sleep and dementia risk

By Carousel Slider, Commentary, In the News
A recent article in the New York Times, How Poor Sleep Affects Your Risk of Dementia, summarizes some recent findings showing both excessively short and long sleep, as well as sleep disorders such as sleep apnea, insomnia, and rapid-eye movement (REM) behavior disorder, may be linked with risk for Alzheimer’s disease (AD) or other forms of dementia. Our recent findings from multiple studies at UCI are consistent with this interpretation. For example, in our most recent study , in collaboration with Alzheimer Biomarkers Consortium — Down Syndrome (ABC-DS) and UCI MIND investigators, we found symptoms of insomnia were more prevalent…
Read More

MIND Matters | Quarterly Newsletter | Spring 2024

By Carousel Slider, Commentary, Community Events, COVID-19, In the News, Participants
Message from the Director   Dear Friends of UCI MIND, Please enjoy the latest issue of MIND Matters from UCI MIND. In this Spring issue, we highlight a number of exciting updates about the impact UCI MIND investigators are having in the field. On the cover, post-doctoral fellow Dr. Claire Butler highlights progress made by the collaborative MODEL-AD group, including a publication she led. Another post-doctoral fellow, Dr. Jessica Noche, highlights an exciting collaboration in which UCI MIND investigators are playing a leading role on the Ann S. Bowers Women’s Brain Health Initiative (page 4). We also highlight several awards…
Read More

FDA Approves Donanemab

By Carousel Slider, Commentary, In the News
Today, the US Food and Drug Administration granted full clinical approval to Eli Lilly to market donanemab, brand name KISUNLA, for the treatment of early Alzheimer’s disease, including Mild Cognitive Impairment (MCI) or mild dementia. Donanemab is a monoclonal antibody against the beta-amyloid protein that accumulates in the brain of people with Alzheimer’s disease. This represents the second ever full approval for a drug that directly targets the biology of Alzheimer’s disease. Image by Andrew Harnik/AP Donanemab was shown in a Phase 2 and then in a Phase 3 trial to have a significant impact on brain amyloid burden. In…
Read More

LA Times article highlights ARIA

By Carousel Slider, Commentary, In the News
A June 17 article in the Los Angeles Times highlighted an important safety risk associated with the new class of medications recently approved for treating Alzheimer’s disease. The drugs are anti-amyloid monoclonal antibodies and include aducanumab, donanemab, and lecanemab. Of these, only lecanemab has achieved full FDA approval at the time of writing. The side effects are collectively known as amyloid-related imaging abnormalities, or ARIA, and are potential side effects for each of these drugs, though with differential frequencies observed across the clinical trials of these medications. The specific drug side effects include what are often referred to as bleeding…
Read More

FDA Advisory Panel meeting held to consider potential approval of donanemab

By Carousel Slider, Commentary, In the News
The U.S. Food and Drug Administration. Today, the FDA convened its Peripheral and Central Nervous System Drugs Advisory Committee to review the data from pivotal clinical trials of donanemab, a monoclonal antibody against the beta amyloid protein that accumulates in the brain of people with Alzheimer’s disease. One of these trials was conducted at UCI MIND. The efficacy of donanemab in treating early Alzheimer’s disease in people with Mild Cognitive Impairment and mild dementia due to Alzheimer’s disease is largely agreed to have been demonstrated. The bulk of the discussion at the meeting emphasized other aspects, such as the safety…
Read More

Dr. Daniel Gillen Named AAAS Fellow

By In the News
Dr. Daniel Gillen Daniel Gillen, PhD, Chancellor's Professor and Chair of Statistics and the leader for the ADRC Data Management and Statistics Core was recently named a fellow of the American Association for the Advancement of Science (AAAS).  Dr. Gillen will be honored in September in Washington D.C. for this rare achievement.
Read More

Dr. Liz Head Named Mentor of the Year by UCI SOM

By Carousel Slider, In the News
The UC Irvine School of Medicine recognized the 2024 best mentors and Elizabeth Head, PhD, Professor and Vice Chair of Research in the Department of Pathology and Laboratory Medicine was awarded the Basic Science Faculty Mentor of the Year.   Dr. Head leads the Research Education Component (REC) of the UCI MIND Alzheimer’s Disease Research Center and  co-leads the TITAN T32 training grant.
Read More

From data to decision-making: the role of machine learning and digital twins in Alzheimer’s Disease

By Carousel Slider, Commentary, In the News
For patients experiencing cognitive decline due to Alzheimer’s Disease (AD), choosing the most appropriate treatment course at the right time is of great importance. A key element to these decisions is the careful consideration of the available scientific evidence, particularly from randomized clinical trials (RCTs) such as the recent lecanemab trial. Translating RCT results into patient-level decisions, however, can be challenging. This is because trial results tell us about the outcomes of groups rather than individuals. A doctor must judge how similar their patient is to the groups studied in trials. For AD, where patients vary widely in clinical presentations…
Read More

Dr. Craig Stark takes UCI’s women’s health research to new heights with the Ann S. Bowers Women’s Brain Health Initiative

By Carousel Slider, In the News
As we celebrate Women's History Month this March, we also find ourselves at a historic moment in scientific inquiry for women’s health research. Today, nearly two-thirds of Americans with Alzheimer’s disease are women, but the underlying cause of this sex disparity is still poorly understood. For decades, research focusing on women's health has been inadequate, with a mere 0.5% of all neuroimaging studies conducted over the past 25 years focusing on women's health. The potential to reach new heights in our understanding of the brain, especially today in the era of “big data” and artificial intelligence, is promising, but requires…
Read More

By In the News
Tianchen Qian, PhD Ahmad Sajjadi, MD, PhD UCI MIND faculty member and UCI Neurologist, Ahmad Sajjadi, MD, PhD, awarded UCI Institute for Precision Health Pilot Award. Dr. Sajjadi will work with Tianchen Qian, PhD, a REC trainee and assistant professor of Statistics at UCI to study early detection of AD using deep machine learning. For a description of the project and to see other awarded projects, click here.   
Read More

FDA delays decision on donanemab

By Carousel Slider, Commentary, In the News
The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein that demonstrated efficacy in early Alzheimer’s disease in a recent Phase 3 clinical trial. A positive decision to approve donanemab had been expected before the end of this month. Though data for donanemab’s ability to lower brain amyloid levels are convincing, the FDA had opted not to grant accelerated approval to the drug, citing limited safety data. This contrasted the agency’s decisions for two other amyloid-lowering drugs, aducanumab and lecanemab…
Read More

MIND Matters | Quarterly Newsletter | Winter 2024

By Carousel Slider, Commentary, Community Events, COVID-19, In the News, Participants
Message from the Director Dear Friends of UCI MIND, Happy New Year! We hope that 2024 is off to a positive start for you. As we embark upon a new year, UCI MIND and the field of Alzheimer’s disease and related dementias (ADRD) research are abuzz with excitement about progress made and opportunities to further advance our field.  At the end of 2023, we held our annual signature fundraising event, the December to Remember Gala. We honored Lauren Miller Rogen and Seth Rogen, the founders of Hilarity for Charity (HFC) and our partners in a program to mentor and inspire…
Read More

Biogen terminates phase 4 efficacy study of aducanumab

By Carousel Slider, In the News
Jessica Rinaldi/The Boston Globe Biogen, the maker of aducanumab has announced that it will terminate the Phase 4 trial required by the FDA for aducanumab, the monoclonal antibody against beta amyloid that received accelerated approval in 2021. The company is also halting production of the compound and relinquishing ownership rights to the original developer, Neurimmune. Accelerated approval was based on the demonstration in multiple studies that treatment with aducanumab could lower brain amyloid in people with Alzheimer’s disease. But two Phase 3 trials gave contrasting results about aducanumab’s efficacy, preventing the FDA from granting full clinical approval for the medication.…
Read More

New Alzheimer’s drugs bring hope. But not equally for all patients.

By Carousel Slider, In the News
The medications have not been widely tested in Black people with the disease, underscoring stark — and persistent — disparities Robert Williford, 67, receives a dose of Leqembi at Abington Neurological Associates in Abington, Pa. (Hannah Yoon for The Washington Post) ABINGTON, Pa. — Wrapped in a purple blanket, Robert Williford settles into a quiet corner of a bustling neurology clinic, an IV line delivering a colorless liquid into his left arm. The 67-year-old, who has early Alzheimer’s disease, is getting his initial dose of Leqembi. The drug is the first to clearly slow the fatal neurodegenerative ailment that afflicts 6.7…
Read More

Studies on negative impacts of sleep deprivation continue to sleep on Blacks

By Carousel Slider, In the News
Black people know intrinsically about the myriad of life areas negatively impacted by the fact that the myth of white supremacy is baked into the foundations of all American institutions. But one area that doesn’t get enough attention is how racism robs Blacks of one of nature’s most powerful healing agents – sleep. Blacks have disproportionately higher rates of sleep disorders (sleep apnea, insomnia, more light and less deep sleep, delayed onset, more daytime sleepiness, and shorter sleep duration) compared to any other racial and ethnic groups in the U.S. These disparities are compounded by the fact that they contribute…
Read More

Sound waves get Alzheimer’s drug past brain barrier, small study shows

By Carousel Slider, In the News
Scientists in an MRI control area plan a focused ultrasound treatment at West Virginia University's Rockefeller Neuroscience Institute. (Victor Finomore/WVU Rockefeller Neuroscience Institute/AP) In the first study of its kind in humans, researchers have discovered that it is safe to use sound waves fired into specific areas of the brain to open a protective barrier and clear the way for Alzheimer’s medications. The study, reported in the New England Journal of Medicine, involved just three patients, but it raises hope about the long-term potential of the treatment strategy known as focused ultrasound. Joshua Grill, professor of psychiatry and human behavior…
Read More

Strategies and habits for a longer, healthier life

By Carousel Slider, In the News
93 colored candles on a cake are being lit. (Getty Images) TAMPA (BLOOM) – Join us as we explore strategies—from mindful living to emerging technologies—and discover how every choice can lead to a longer and healthier life. Welcome to the science of aging, where the pursuit of health and happiness is the entire goal. Lifestyle Habits for Longevity Avoiding Harmful Substances In the pursuit of a longer, healthier life, steering clear of harmful substances is an obvious decision. Dr. Claudia Kawas, a distinguished neurologist at the University of California, Irvine, sounds the alarm on two major culprits: smoking and excessive alcohol…
Read More

Celebrating What’s Right With Aging: Inside the Minds of Super Agers

By Carousel Slider, In the News
Some people in their 80s and 90s show shockingly little decline in their brainpower. Scientists are beginning to understand what makes them different and how the rest of us might benefit Mark Ross Studio / Getty You can find Vernon Smith hard at work at his computer by 7:30 each morning, cranking out 10 solid hours of writing and researching every day. His job is incredibly demanding — he is currently on the faculty of both the business and law schools at Chapman University. But the hard work pays off: Smith’s research is consistently ranked as the most-cited work produced…
Read More

Researchers testing out drug for Alzheimer’s prevention

By Carousel Slider, In the News
More than 6 million Americans have Alzheimer's disease, and the CDC expects that number to double in the next three decades. Photo by: Manuel Balce Ceneta / AP The first drug fully approved by the FDA for Alzheimer’s has been on the market for 10 months. Now, researchers are looking at testing it to prevent Alzheimer's. A shot that could one day prevent Alzheimer's disease — that’s the potential future for lecanemab, or Leqembi. Researchers are studying to see if the drug can prevent the disease. "We hope make breakthroughs in discoveries that change our ability to help people in their…
Read More

More good news from CMS

By Carousel Slider, In the News
On Friday October 13, 2023, the Centers for Medicare and Medicaid Services (CMS) announced a formal change to their coverage policy for amyloid PET imaging. Previously, with limited exceptions, patients were required to be enrolled in a clinical study known as “Coverage with Evidence Determination” for the scan to be reimbursed. Now, that requirement has been removed and the door has been opened for more patients to get the scan and result in savings of thousands of dollars for patients and their families. In fact, patients may have the opportunity to receive multiple covered scans as part of their routine care…
Read More

How Old is Too Old to Govern?

By Carousel Slider, In the News
Most Americans favor an age limit for the president and other politicians. But some ethicists and scientists argue that’s ageist and scientifically unsound. Photos via Wikimedia Commons (left: Joint Congressional Committee; right: Gage Skidmore) Barring a considerable shift in the political winds, the next US president will be either 82 or 78 years old on Inauguration Day. Meanwhile, Senate Minority Leader Mitch McConnell, who twice froze in front of cameras and was unable to speak for several agonizing moments, is 81. His Democratic counterpart, Majority Leader Chuck Schumer, is a comparative spring chicken at 72. Senator Dianne Feinstein died last month…
Read More

The Secret to Living to 100? It’s Not Good Habits

By Carousel Slider, In the News
iStock Neurologist Dr. Claudia Kawas has been tracking the habits of the “oldest old,” those older than 90, in Southern California since 2003, as part of a study at the University of California, Irvine. She and a team of researchers have found links between longevity and even short amounts of exercise, social activities such as going to church, and modest caffeine and alcohol intake. Read the article here.
Read More

Hispanic Americans are at higher risk of developing Alzheimer’s disease, research shows

By Carousel Slider, In the News
Hispanic people are 1.5 times more likely to develop Alzheimer's. ‘Our America: Unforgettable’The documentary special, produced by ABC Owned Television Stations in partnership with ABC News, takes a looks at alarming data on Alzheimer’s disease through a Hispanic and Latino lens. Nearly 7 million Americans live with Alzheimer's disease, an irreversible and devastating form of dementia that gradually breaks down memory and thinking skills. But not everyone is equally at risk. Hispanic people are 1.5 times more likely to develop Alzheimer's disease than white people, according to data from the Alzheimer's Association. "Our America: Unforgettable" is an hour-long special produced by ABC Owned…
Read More

UCI Summer Institute Trains Undergraduates in Biostatistics and Data Science

By Carousel Slider, In the News
This summer, UC Irvine was again one of only 10 universities in the U.S. to host a free six-week program to train undergraduate students in the fundamentals of biostatistics, data science and computing. For the second year in a row, the Irvine Summer Institute in Biostatistics and Undergraduate Data Science (ISI-BUDS) brought students to UCI from across the nation and, as part of the training, offered hands-on experience conducting cutting-edge biomedical research. The ISI-BUDS Program Of the more than 150 applicants, 15 students were selected for the highly competitive program, which includes up to $500 in travel expenses, free housing,…
Read More

OC Racism: Bad for Brain Health

By Carousel Slider, In the News
Whatever keeps the community up at night – or makes them pull the covers over their head to not face the day – probably won’t surface for years to come, but Dr. Karen Lincoln sees where it starts in the early stages through brain imaging. In and of itself, she said it’s not so much about sleep, but rather why advanced aging disproportionately impacts the Black community. Two of her landmark studies, Sleep Tight and Express Yourself, show how and why everyday discrimination and microaggressions are taking a dramatic toll on health. Earlier this year, Dr. Lincoln joined UCI faculty…
Read More

Dianne Feinstein’s cause of death hasn’t been disclosed, but it likely wasn’t dementia

By Carousel Slider, In the News
Sen. Dianne Feinstein during a committee hearing in 2022. (J. Scott Applewhite / Associated Press) No cause of death has been disclosed for Dianne Feinstein, the longtime California senator who struggled with evident health problems in her final years before her death Friday. She was absent from the U.S. Senate for nearly three months earlier this year while recovering from a case of shingles that led to encephalitis, a rare complication that causes inflammation and swelling in the brain. She was briefly hospitalized in August after falling at her home and was often seen in a wheelchair in public. Indications that Feinstein, 90, was struggling with memory problems have…
Read More